Recently published studies showed that mutant NRAS melanoma and neuroblastoma cells are highly sensitive to the combination of MEK and combined PI3K/mTOR inhibitors which are in preclinical or early clinical development [13, 15]. This evidence concerns the gene MTOR and neuroblastoma.